Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keisuke Yusa is active.

Publication


Featured researches published by Keisuke Yusa.


Biochemical and Biophysical Research Communications | 1990

Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells

Wakao Sato; Keisuke Yusa; Mikihiko Naito; Takashi Tsuruo

Staurosporine, a potent inhibitor of C-kinase, enhances accumulation of vincristine (VCR) in multidrug-resistant cells. We investigated this enhancement by two methods: (I) ATP-dependent VCR binding system; (II) azidopine photolabeling system. The ATP-dependent VCR binding to the resistant cell membrane was inhibited more efficiently by staurosporine than by verapamil. Staurosporine also inhibited the azidopine photolabeling of P-glycoprotein. These results indicate that staurosporine, an inhibitor of C-kinase, might directly bind to P-glycoprotein as well as antitumor agents and Ca2+ channel blockers. These findings also indicate that C-kinase might be involved in the function of P-glycoprotein.


Biochemical and Biophysical Research Communications | 1989

Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein.

Mikihiko Naito; Keisuke Yusa; Takashi Tsuruo

Multidrug-resistant cells are characterized by the presence of P-glycoprotein on the plasma membrane, which binds and probably transports antitumor agents outside the cells. P-glycoprotein is also present in various normal tissues such as the adrenal gland. To investigate the physiological function of P-glycoprotein, we examined possible endogenous materials which inhibit the binding of vincristine to the resistant cell membrane. The binding was inhibited by steroid hormones, most efficiently by progesterone. Progesterone also reduced the photoaffinity labeling of P-glycoprotein by a photoactive analogue of vindesine. These results suggest that P-glycoprotein in the adrenal gland could have a role in the secretion of steroid hormones.


Cancer Chemotherapy and Pharmacology | 1988

Comparison of glutathione S-transferase activity between drug-resistant and-sensitive human tumor cells: Is glutathione S-transferase associated with multidrug resistance?

Keisuke Yusa; Hirofumi Hamada; Takashi Tsuruo

SummaryWe have studied the levels of glutathione S-transferase in drug-resistant and-sensitive human tumor cell lines to examine a possible involvement of glutathione S-transferase (GST) in multidrug resistance mechanisms. No increase in the activity of glutathione S-transferase was detected in myelogenous leukemia K562 resistant to adriamycin (K562/ADM), ovarian carcinoma cell line A2780 resistant to adriamycin (2780AD), or acute lymphoblastic leukemia cell line CCRF-CEM resistant to vinblastine (CEM-VLB100), compared with the drug-sensitive parent tumor cells. The human breast cancer cell lines Hattori and MCF-7 had a 12- to 63-fold lower level of glutathione S-transferase activity than K562, A2780, CCRF-CEM, and their drug-resistant sublines. Induction of ADM resistance in Hattori did not increase the activity of glutathione S-transferase. However, induction of colchicine resistance in MCF-7 resulted in a 70-fold increase in the activity of glutathione S-transferase. A revertant of the colchicine-resistant MCF-7 contained a level of glutathione S-transferase activity similar to that of the resistant subline. The increase of glutathione S-transferase activity did not alter the sensitivity of the cell to cytotoxic drugs. The increased activity was due to the appearance of glutathione S-transferase π, as shown by enzyme inhibition using anti-glutathione S-transferase π antibody. Our findings indicate that increased cellular glutathione S-transferase activity is not associated with the development of multidrug resistance.


Biochemical and Biophysical Research Communications | 1990

Cross-resistance to anti-HIV nucleoside analogs in multidrug-resistant human cells

Keisuke Yusa; Tomoko Oh-hara; Akiko Yamazaki; Satomi Tsukahara; Wakao Satoh; Takashi Tsuruo

Human multidrug-resistant K562/ADM cells showed 12-fold and 31-fold resistance to AZT (3-azido-2, 3dideoxythymidine) and DDC (2, 3-dideoxycytidine), respectively. Other multidrug-resistant human cells CEM/VLB100 and AdrRMCF-7 also showed resistance to these nucleoside analogs. However, verapamil (10 microM) failed to reverse the resistance to the nucleoside analogs. Accumulation of [3H]AZT in human multidrug-resistant K562/ADM, CEM/VLB100 and AdrRMCF-7 cells decreased by 23, 35, and 42% respectively, as compared to their parental cells. These results suggest that anti-HIV nucleoside analogs including AZT, DDC could be transported by outward drug-transport system in the multidrug-resistant cells.


Biochemical and Biophysical Research Communications | 1992

Resolution of 9-(c-4,t-5-bishydroxymethylcyclopent-2-en-r-1-yl)-9H-adenine and selective inhibition of human immunodeficiency virus by the (−) enantiomer

Nobuya Katagiri; Takuya Shiraishi; Hiroshi Sato; Akemi Toyota; Chikara Kaneko; Keisuke Yusa; Tomoko Oh-hara; Takashi Tsuruo

Two enantiomers of 9-(c-4,t-5-bishydroxymethylcyclopent-2-en-r-1-yl)-9H- adenine (BCA) which showed a potent and selective anti-HIV effects have been synthesized and evaluated against human immunodeficiency virus type 1. The result demonstrated that the potent-HIV activity of racemic BCA is expressed solely by the (-) isomer.


Antiviral Research | 1994

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins

Keisuke Yusa; Tomoko Oh-hara; Satomi Tsukahara; Kimiye Baba; Masahiko Taniguchi; Mitsugi Kozawa; Saeko Takeuchi; Hiroshi Hara; Takashi Tsuruo

Three flavans, daphnodorins A, B and C isolated from Dahpne odora THUNB. were tested for their abilities to inhibit human immunodeficiency virus type 1 (HIV-1(IIIB)) replication in MT-4 cells. The effective concentrations (EC50) of daphnodorins A, B and C against HIV-1-induced cytolysis were 0.26 +/- 0.08, 1.8 +/- 0.6 and 3.6 +/- 0.5 micrograms/ml, respectively. Also these three compounds showed inhibitory effects of p24 antigen in human peripheral blood lymphocytes. As compared with 2,3-dideoxycytidine 5-triphosphate (DDC-TP), daphnodorin A and daphnodorin C had relatively weak inhibitory effects on the reverse transcriptase of HIV-1, while daphnodorin B did not show any inhibitory effect at concentrations up to 1000 micrograms/ml. These three compounds showed marked inhibitory effects on syncytium formation between HIV-1(IIIB)-infected and uninfected MOLT-4 (clone 8) cells at 3-30 micrograms/ml without inducing cytotoxicity. The concentrations of the compounds blocking syncytium formation were consistent with the effective concentrations (EC50) against HIV-induced cytolysis of MT-4 cells. These results, differing from reverse transcriptase inhibitors, suggest that the daphnodorins exert their anti-HIV-1 activity through inhibition of early events of viral replication including adsorption of the virions to the cells or the subsequent entry.


Biochimica et Biophysica Acta | 1995

Activation of silent MDR1 genes in revertant cells by fusion with multidrug-resistant cells

Keisuke Yusa; Junko Tamura; Atsuo Waki; Takashi Tsuruo

We isolated revertant and resistant clones from multidrug-resistant K562/ADM cells and evaluated the expression of P-glycoprotein and the DNA copy number of MDR1. The 9 revertant clones contained 2- to 26-fold DNA copies of MDR1; however, they expressed an extensively decreased P-glycoprotein compared with K562/ADM, while the 10 multidrug-resistant clones contained 4- to 48-fold DNA copies, and the expression level of P-glycoprotein was dependent on the copy number of MDR1 DNA. The decreased expression of P-glycoprotein in the revertants was not due only to the loss of the copy number of MDR1 DNA. To elucidate the mechanism of P-glycoprotein expression decrease in the revertants, a revertant clone (R1-5) was fused with a multidrug-resistant clone (A2-1) or with a drug-sensitive clone isolated from K562. Compared with K562 clone, the A2-1 contained 32-fold MDR1 DNA copies and showed 131-fold resistance to Adriamycin. The revertant clone R1-5 contained 26-fold MDR1 DNA copies but expressed only 5% the P-glycoprotein of A2-1 cells and showed only 2-fold resistance to Adriamycin. For selection of intraspecific hybrids, a neomycin-resistant or a blasticidin S-resistant gene was introduced into clones by electroporation of pSV2neo or pSV2bsr. The introduction of these resistant genes did not alter the copy number or expression of MDR1 in the clones. Hybrid cells between R1-5bsr and A2-1neo were found to express 136 +/- 15% of the P-glycoprotein of A2-1 cells evaluated by quantitive flow cytometry. These hybrid cells contained 41- to 48-fold MDR1 copies and showed the multidrug-resistant phenotype, such as decrease of rhodamine123 accumulation and 120- to 210-fold resistance to Adriamycin (compared with K562), indicating that the silent MDR1 genes in the revertant clone R1-5 were activated by cell fusion with an MDR clone. R1-5bsr x K562neo hybrids were found to contain 8- to 11-fold MDR1 copies and there was no increase in P-glycoprotein expression as compared with R1-5.


Cancer Research | 1989

Reversal Mechanism of Multidrug Resistance by Verapamil: Direct Binding of Verapamil to P-Glycoprotein on Specific Sites and Transport of Verapamil Outward across the Plasma Membrane of K562/ADM Cells

Keisuke Yusa; Takashi Tsuruo


Journal of Medicinal Chemistry | 1992

Synthesis and anti-HIV activity of 9-[c-4,t-5-bis(hydroxymethyl)cyclopent-2-en-r-1-yl]-9H-adenine.

Nobuya Katagiri; Masahiro Nomura; Hiroshi Sato; Chikara Kaneko; Keisuke Yusa; Takashi Tsuruo


Cancer Research | 1991

Circumvention of Multidrug Resistance by a Newly Synthesized Quinoline Derivative, MS-073

Wakao Sato; Nobuyuki Fukazawa; Tsuneji Suzuki; Keisuke Yusa; Takashi Tsuruo

Collaboration


Dive into the Keisuke Yusa's collaboration.

Top Co-Authors

Avatar

Takashi Tsuruo

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Tomoko Oh-hara

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Satomi Tsukahara

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Wakao Sato

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Yoshikazu Sugimoto

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge